CONCENTER BIOPHARMA as a 2018 TiE50 Finalist.

TiE Inflect 2018 announces CONCENTER BIOPHARMA as a 2018 TiE50 Finalist.

TiE50 Finalist

CONCENTER BIOPHARMA is excited to announce that it has been selected as a "2018 TiE50 Finalist" for the prestigious TiE50 Awards Program recognizing the world's most innovative tech startups. This awards competition is part of TiE Inflect 2018, the world's largest conference for tech entrepreneurs.

"We are honored and excited to have been chosen as a finalist out of over 7000 companies from around the world! Our plan is to begin clinical trials for our Type 2 Diabetes drug in the coming months..." said Dror Chevion, Co-Founder and CEO of the company. canagliflozin. "TiE50 has become a global brand that attracts thousands of tech startups worldwide. This year, we screened more than 7400 companies from 28 countries and selected the best-of-breed as our "2018 TiE50 Finalists".


These companies are finalists in the ultimate runoff for the 50 winners.


Our program has gained notoriety over the past decade as a competition run with the highest level of integrity and vigorous screening and judging by domain experts".

Kamal Anand, TiE50 Program Chair "As a 26-year not-for-profit dedicated to fostering entrepreneurship and with a global footprint of half million entrepreneurs, enterprise executives, and investment professionals, we pride in the fact that we are one of very few competitions without any pay-to-play incentives" Ram K. Reddy, President, TiE Silicon Valley.


LINKS TO :


1. TiE Inflect 2018


2. IATI PREES RELEASE


3. Read More





Hi, thanks for stopping by!

Concenter BioPharma is a subsidiary of Silkim Pharma Ltd., which developed a novel, protected PLATFORM of drugs for proven treatments of multiple indications. 

 

Our PLATFORM is the result of extensive investigation of animal models of human diseases.

Let the news
come to you.

  • LinkedIn
  • Facebook
  • Twitter

CONTACT US

Thank you for your interest in Concenter BioPharma.

To contact us please reach us via: